Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XyloCor doses patients in phase 1/2 trial evaluating XC001 in refractory angina
XyloCor doses patients in phase 1/2 trial evaluating XC001 in refractory angina. (Credit: Mahmoud Ahmed from Pixabay)
XyloCor doses patients in phase 1/2 trial evaluating XC001 in refractory angina. (Credit: Mahmoud Ahmed from Pixabay)